双歧杆菌三联活菌胶囊联合水飞蓟宾治疗非酒精性脂肪性肝炎患者疗效及对肠道菌群的影响  

Therapeutic effect of Bifidobacterium triple active bacteria capsule combined with Silymarin on non-alco-holic steatohepatitis patients and its impact on gut microbiota

作　　者：陈忆青 陈小莹 Chen Yiqing;Chen Xiaoying(Department ofGeneral Practice,Taizhou First People′s Hospital,Taizhou,Zhejiang 318020,China)

机构地区：[1]台州市第一人民医院全科医学科,浙江台州318020

出　　处：《中国药物与临床》2024年第23期1539-1543,共5页Chinese Remedies & Clinics

摘　　要：目的探讨双歧杆菌三联活菌胶囊联合水飞蓟宾治疗非酒精性脂肪性肝炎患者疗效及对肠道菌群的影响研究。方法选取浙江省台州市第一人民医院收治138例非酒精性脂肪性肝炎患者,根据治疗方案不同分为3组,采用水飞蓟宾治疗者46例为水飞蓟宾组,采用双歧杆菌三联活菌胶囊治疗者46例为双歧杆菌三联活菌胶囊组,采用双歧杆菌三联活菌胶囊组联合水飞蓟宾治疗者46例为联合组。比较3组临床疗效、粪便中肠道菌群、肝功能、血清内毒素等指标。结果联合组临床总有效率(95.6%)优于水飞蓟宾组(78.3%)、双歧杆菌三联活菌胶囊组(82.6%)(χ^(2)=5.842、4.127,P均<0.05);水飞蓟宾组与双歧杆菌三联活菌胶囊组总有效率比较差异无统计学意义(χ^(2)=0.963,P>0.05);联合组治疗后双歧杆菌、乳杆菌数量高于水飞蓟宾组、双歧杆菌三联活菌胶囊组(t=4.731、3.710、4.124、3.752,P均<0.05),葡萄球菌、肠杆菌数量低于水飞蓟宾组、双歧杆菌三联活菌胶囊组(t=3.152、3.853、4.117、3.924,P均<0.05);联合组治疗后血清丙氨酸氨基转移酶、天冬氨酸氨基转移酶、内毒素水平及体质量指数均低于水飞蓟宾组、双歧杆菌三联活菌胶囊组(t=4.942、5.113、3.758、3.165、4.073、3.250、4.114、3.541,P均<0.05)。结论双歧杆菌三联活菌胶囊联合水飞蓟宾治疗可有效调节非酒精性脂肪性肝炎患者肠道菌群失调,改善肝功能,降低血清内毒素水平,具有显著疗效。Objective To explore the efficacy of bifidobacterium triple viable capsules combined with silybin in the treatment of non-alcoholic steatohepatitis patients and its impact on gut microbiota.Methods A total of 138 patients with non-alcoholic steatohepatitis admitted to our hospital′s infection department were selected and divided into three groups:Silymarin group(treated with Silymarin),Bifidobacterium triple active bacteria capsule group(treated with Bifidobacterium triple active bacteria capsule),and combination group(treated with Bifidobacterium triple active bacteria capsule group),with 46 cases in each group.The clinical efficacy,fecal microbiota,liver function,serum endotoxin and other indicators of the three groups were compared.Results The clinical total effective rate of the combination group(95.6%)was significantly better than that of the Silymarin group(78.3%)and the Bifidobacterium triple active capsule group(82.6%)(χ^(2)=5.842,4.127,all P<0.05);there was no significant difference in the total effective rate between the Silymarin group and the Bifidobacterium triple active capsule group(χ^(2)=0.963,P>0.05);After treatment,the number of Bifidobacterium and Lactobacillus in the combination group was higher than that of the Silymarin group and the Bifidobacterium triple active capsule group(t=4.731,3.710,4.124,3.752,all P<0.05),while the number of Staphylococcus and Escherichia coli was significantly lower than that of the Silymarin group and the Bifidobacterium triple active capsule group(t=3.152,3.853,4.117,3.924,all P<0.05);Serum ALT,AST The levels of endotoxins and BMI were significantly lower in the Silymarin group and Bifidobacterium triple active capsules group(t=4.942,5.113,3.758,3.165,4.073,3.250,4.114,3.541,all P<0.05).Conclusion The combination of bifidobacterium triple viable capsules and silybin treatment can effectively regulate the imbalance of intestinal microbiota in patients with non-alcoholic steatohepatitis,improve liver function,reduce serum endotoxin levels,and have significant t

关 键 词：水飞蓟宾 非酒精性脂肪性肝病 双歧杆菌三联活菌胶囊 治疗结果 胃肠道微生物组 

分 类 号：R575.5[医药卫生—消化系统]